|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"shan ys"
Showing items 61-110 of 133 (3 Page(s) Totally)
<< < 1 2 3 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2020-05-04 |
The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: Real-world experience in a Taiwanese cohort
|
Su, YY;Chiang, NJ;Tsai, HJ;Yen, CJ;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2020-05 |
Exploring Circulating Tumor Cells in cholangiocarcinoma using a novel glycosaminoglycan probe on a microfluidic platform
|
Gopinathan, P;Chiang, NJ;Bandaru, A;Sinha, A;Huang, WY;Hung, SC;Shan, YS;Lee, GB |
| 國家衛生研究院 |
2020-01 |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma–TCOG T1211 study
|
Chiang, NJ;Tsai, KK;Hsiao, CF;Yang, SH;Hsiao, HH;Shen, WC;Hsu, C;Lin, YL;Chen, JS;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2020-01 |
DUSP2 regulates extracellular vesicle-VEGF-C secretion and pancreatic cancer early dissemination
|
Wang, CA;Chang, IH;Hou, PC;Tai, YJ;Li, WN;Hsu, PL;Wu, SR;Chiu, WT;Li, CF;Shan, YS;Tsai, SJ |
| 國家衛生研究院 |
2019-12-18 |
An open-label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy of TLC388 and genomic analysis for poorly differentiated neuroendocrine carcinomas
|
Chen, MH;Chou, WC;Hsiao, CF;Jiang, SS;Tsai, HJ;Liu, YC;Hsu, C;Shan, YS;Hung, YP;Hsich, CH;Chiu, CH;Liu, TC;Cho, SF;Liu, TW;Chao, Y |
| 國家衛生研究院 |
2019-12-01 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study
|
Bang, YJ;Li, CP;Lee, KH;Chiu, CF;Park, JO;Shan, YS;Kim, JS;Chen, JS;Shim, HJ;Rau, KM;Choi, HJ;Oh, DY;Belanger, B;Chen, LT |
| 國家衛生研究院 |
2019-09 |
Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8
|
Wang, HC;Lin, YL;Hsu, CC;Chao, YJ;Hou, YC;Chiu, TJ;Huang, PH;Tang, MJ;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2019-08-29 |
The differential distributions of ASPM isoforms and their roles in Wnt signaling, cell cycle progression, and pancreatic cancer prognosis
|
Hsu, CC;Liao, WY;Chan, TS;Chen, WY;Lee, CT;Shan, YS;Huang, PJ;Hou, YC;Li, CR;Tsai, KK |
| 國家衛生研究院 |
2019-07-30 |
Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors
|
Hsueh, YS;Chang, HH;Shan, YS;Sun, HS;Fletcher, JA;Li, CF;Chen, LT |
| 國家衛生研究院 |
2019-07-26 |
The epidemiology of gastric cancers in the era of Helicobacter pylori eradication: A nation-wide cancer registry-based study in Taiwan
|
Chang, JS;Kuo, SH;Chu, PY;Shan, YS;Tsai, CR;Tsai, HJ;Chen, LT |
| 國家衛生研究院 |
2019-07 |
Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer
|
Hsu, MC;Tsai, YL;Lin, CH;Pan, MR;Shan, YS;Cheng, TY;Cheng, SHC;Chen, LT;Hung, WC |
| 國家衛生研究院 |
2019-05-20 |
Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer
|
Weng, CC;Hsieh, MJ;Wu, CC;Lin, YC;Shan, YS;Hung, WC;Chen, LT;Cheng, KH |
| 國家衛生研究院 |
2019-02 |
Mutational landscape by targeted next-generation sequencing in EBV-associated lymphoepithelioma-like cholangiocarcinoma
|
Chiang, NJ;Chen, MH;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2019-01 |
Beta-catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer
|
Kuo, TL;Cheng, KH;Shan, YS;Chen, LT;Hung, WC |
| 國家衛生研究院 |
2018-12-20 |
Protein arginine methyltransferase 3 enhances chemoresistance in pancreatic cancer by methylating hnRNPA1 to increase ABCG2 expression
|
Hsu, MC;Pan, MR;Chu, PY;Tsai, YL;Tsai, CH;Shan, YS;Chen, LT;Hung, WC |
| 國家衛生研究院 |
2018-12 |
c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation
|
Chang, TM;Shan, YS;Chu, PY;Lin, HY;Huang, KW;Hung, WC;Chen, LT;Tsai, HJ |
| 國家衛生研究院 |
2018-12 |
The epidemiology of gastric cancer in the era of H. pylori eradication: A nation-wide registry-based study in Taiwan
|
Tsai, HJ;Chang, JS;Shan, YS;Tsai, CR;Chen, LT |
| 國家衛生研究院 |
2018-11-07 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
|
Chen, LT;Siveke, JT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, FS;Mamlouk, K;Belanger, B;de Jong, FA;Hubner, RA |
| 國家衛生研究院 |
2018-11 |
TCOG T1308 study: The final results of a phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer
|
Chiang, NJ;Chen, LT;Chen, JS;Yang, SH;Hsu, C;Shan, YS;Yen, CJ;Chen, MH;Tsou, HH |
| 國家衛生研究院 |
2018-10 |
Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study
|
Chiang, NJ;Tsai, KK;Chen, JS;Yang, SH;Hsiao, HH;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2018-10 |
Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study
|
Chang, HJ;Chiu, YF;Chen, JS;Li, CP;Ho, CL;Shyr, YM;Chiou, WC;Yeh, CN;Hsieh, RK;Lin, YL;Tien, YW;Hwang, TL;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2018-09-27 |
The incidence and survival of pancreatic cancer by histology, including rare subtypes: A nation-wide cancer registry-based study from Taiwan
|
Chang, JS;Chen, LT;Shan, YS;Chu, PY;Tsai, CR;Tsai, HJ |
| 國家衛生研究院 |
2018-04-07 |
The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients
|
Hung, YP;Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2018-03 |
Cure of unresectable, locally advanced pancreatic cancer after multidisciplinary therapy
|
Kao, TM;Liu, YS;Shan, YS;Ch'ang, HJ;Chen, LT |
| 國家衛生研究院 |
2018-01 |
Environmental tobacco smoke and risk of pancreatic cancer among never smokers
|
Tsai, CR;Chang, JS;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2018-01 |
The role of aberrant mitochondrial phosphoenolpyruvate carboxykinase expression in pancreatic neuroendocrine tumors
|
Tsai, HJ;Chu, PY;Jiang, SS;Shan, YS;Hung, WC;Chen, MH;Lin, HY;Chen, YL;Chen, LT |
| 國家衛生研究院 |
2017-11 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI65-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
|
Blanc, JF;Hubner, R;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Mercade, TM;Lee, KH;Cunningham, D;Chiu, CF;Schwartsmann, G;Braiteh, F;von Hoff, D;Chen, LT;Mamlouk, K;de Jong, F;Siveke, J |
| 國家衛生研究院 |
2017-11 |
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) � 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Wang-Gillam, A;Shan, YS;Mercade, TM;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, J;Belanger, B;de Jong, F;Mamlouk, K;von Hoff, D |
| 國家衛生研究院 |
2017-10-09 |
Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors
|
Chu, PY;Jiang, SS;Shan, YS;Hung, WC;Chen, MH;Lin, HY;Chen, YL;Tsai, HJ;Chen, LT |
| 國家衛生研究院 |
2017-09-16 |
The regulatory role of aberrant Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors
|
Chang, TM;Shan, YS;Chu, PY;Jiang, SS;Hung, WC;Chen, YL;Tu, HC;Lin, HY;Tsai, HJ;Chen, LT |
| 國家衛生研究院 |
2017-09 |
Screening of peptide specific to cholangiocarcinoma cancer cells using an integrated microfluidic system and phage display technology
|
Yu, CW;Fu, CY;Hung, LY;Wang, CH;Chiang, NJ;Wang, YC;Shan, YS;Lee, GB |
| 國家衛生研究院 |
2017-09 |
Mutant KIT translocates into the nucleus and induces NFKBIB expression that leads to KIT expression in imatinib-resistant gastrointestinal stromal tumors
|
Hsueh, YS;Chang, HH;Shan, YS;Sun, HS;Fletcher, JA;Li, CF;Chen, LT |
| 國家衛生研究院 |
2017-07-01 |
Automated selection of aptamers against cholangiocarcinoma cells on an integrated microfluidic platform
|
Gopinathan, P;Hung, LY;Wang, CH;Chiang, NJ;Wang, YC;Shan, YS;Lee, GB |
| 國家衛生研究院 |
2017-06-26 |
A microfluidic chip for detecting cholangiocarcinoma cells in human bile
|
Hung, LY;Chiang, NJ;Tsai, WC;Fu, CY;Wang, YC;Shan, YS;Lee, GB |
| 國家衛生研究院 |
2017-06-26 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
|
Jean-Frederic, B;Richard, H;Li, CP;Andrea, WG;Gyorgy, B;Andrew, D;Shan, YS;Gayle, J;Teresa, M;Lee, H;David, C;Chiu, CF;Gilberto, S;Fadi, B;Daniel, V;Chen, LT;Khalid, M;Parul, B;Floris, D;Jens, S |
| 國家衛生研究院 |
2017-06-26 |
CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) +/- 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Andrea, WG;Shan, YS;Teresa, M;Jean-Frederic, B;Richard, H;Chiu, CF;Gilberto, S;Jens, S;Marc, PJ;Bruce, B;Floris, D;Khalid, M;Daniel, V |
| 國家衛生研究院 |
2017-02 |
A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer
|
Chiang, NJ;Chen, JS;Chen, MH;Yang, SH;Hsu, C;Yen, CJ;Tsou, HH;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2016-12 |
The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan
|
Liu, CT;Chen, MH;Chen, JS;Chen, LT;Shan, YS;Lu, CH;Su, YL;Ku, FC;Chou, WC;Chen, YY |
| 國家衛生研究院 |
2016-12 |
Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells
|
Chan, TS;Hsu, CC;Pai, VC;Liao, WY;Huang, SS;Tan, KT;Yen, CJ;Hsu, SC;Chen, WY;Shan, YS;Li, CR;Lee, MT;Jiang, KY;Chu, JM;Lien, GS;Weaver, VM;Tsai, KK |
| 國家衛生研究院 |
2016-12 |
Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study
|
Chen, LT;Li, CP;Chiu, CF;Shan, YS;Park, JO;Chen, JS;Kim, JS;Rau, KM;de Jong, F;Pipas, M;Belanger, B;Wang, E;Lee, KH;Bang, YJ |
| 國家衛生研究院 |
2016-12 |
Sequential use of everolimus and sunitinib in treating WHO grade 1 and 2 pancreatic neuroendocrine tumors-retrospective multi-center study in Taiwan
|
Liu, CT;Chen, LT;Chen, YY;Chen, JS;Su, YL;Chou, WC;Lu, CH;Ku, FC;Chen, MH;Shan, YS |
| 國家衛生研究院 |
2016-11 |
Role of epigenetic regulator EHMT2 in the regulation of gemcitabine resistance in pancreatic cancer
|
Hung, WC;Pan, MR;Hsu, MC;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2016-10 |
Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Braiteh, F;Belanger, B;Bayever, E;de Jong, F;von Hoff, DD;Siveke, JT |
| 國家衛生研究院 |
2016-10 |
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther
|
Hubner, RA;Chen, LT;Siveke, JT;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, F;Mamlouk, K;Belanger, B;de Jong, F;von Hoff, DD;Wang-Gillam, A |
| 國家衛生研究院 |
2016-09 |
The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer
|
Pan, MR;Hsu, MC;Luo, CW;Chen, LT;Shan, YS;Hung, WC |
| 國家衛生研究院 |
2016-07 |
KIT exon 11 codons 557-558 deletion mutation promotes liver metastasis through the CXCL12/CXCR4 axis in gastrointestinal stromal tumors
|
Wang, HC;Li, TY;Chao, YJ;Hou, YC;Hsueh, YS;Hsu, KH;Shan, YS |
| 國家衛生研究院 |
2016-07 |
Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer
|
Chiang, NJ;Chang, JY;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2016-05-03 |
Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer
|
Chiang, NJ;Hsu, C;Chen, JS;Tsou, HH;Shen, YY;Chao, Y;Chen, MH;Yeh, TS;Shan, YS;Huang, SF;Chen, LT |
| 國家衛生研究院 |
2016-05 |
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E;Von Hoff, DD;Chen, LT |
| 國家衛生研究院 |
2016-02 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, F;Moyo, V;Belanger, B;Dhindsa, N;Bayever, E;Von Hoff, DD;Chen, LT;the NAPOLI-1 Study Group. |
Showing items 61-110 of 133 (3 Page(s) Totally)
<< < 1 2 3 > >>
View [10|25|50] records per page
|
